Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

FDA Data Sharing Mandate Escalates; CGT Industry Faces System-Wide Transparency Shift

The cell and gene therapy (CGT) industry is facing growing pressure to transform how it develops, manufactures, and commercializes advanced therapies, according to industry experts speaking ahead of BIO 2026. In discussions highlighted by BioSpace on June 22, 2026, leaders
  • News
FDA Data Sharing Mandate Escalates; CGT Industry Faces System-Wide Transparency Shift

Pharma Confidence Surges in 2026; While Record M&A and IPO Activity Defy Geopolitical Pressure

Biopharmaceutical industry confidence reached a four-year high in early 2026, according to GlobalData’s State of the Biopharmaceutical Industry 2026 Mid-Year Update, based on a survey of 157 professionals. The report shows 55% of respondents are optimistic about growth despite geopolitical
  • News
Pharma Confidence Surges in 2026; While Record M&A and IPO Activity Defy Geopolitical Pressure

Pharma Deal Slowdown Hits Q1 2026; As AI Partnerships Replace Traditional M&A Logic

Pharma dealmaking slowed in early 2026 as buyers tightened valuation discipline and increased diligence across life sciences transactions. AI partnerships, manufacturing acquisitions, and oncology consolidation are shaping the next phase of pharma deal activity, with recovery expected in late 2026
  • News
Pharma Deal Slowdown Hits Q1 2026; As AI Partnerships Replace Traditional M&A Logic

CNPV Promises Faster Drug Reviews; But Timeline Consistency Breaks

The Food and Drug Administration has introduced its Commissioner’s National Priority Voucher (CNPV) pilot program to accelerate drug and biologic review timelines in the United States. According to industry analysis by Lifescience Dynamics, the program aims to reduce approval timelines
  • News
CNPV Promises Faster Drug Reviews; But Timeline Consistency Breaks

FDA Shock U-Turn on mRNA-1010; From Rejection to Unanimous Vote

Pharmaceutical Executive Daily reports that the FDA Vaccines and Related Biological Products Advisory Committee unanimously voted 9–0 in favor of Moderna’s investigational mRNA-1010 seasonal influenza vaccine for adults aged 50–64 and 65+. The committee confirmed that the benefit-risk profile supports
  • News
FDA Shock U-Turn on mRNA-1010; From Rejection to Unanimous Vote

200 ADC Biotechs in China Raise Pressure on Daiichi Sankyo; as Global Oncology Race Intensifies

At ASCO 2026 in Chicago, Daiichi Sankyo R&D chief John Tsai outlined a long-term strategy to expand antibody-drug conjugate innovation using AI and data-driven biology. The company plans to build at least two new ADC platforms by 2030 while facing
  • News
200 ADC Biotechs in China Raise Pressure on Daiichi Sankyo; as Global Oncology Race Intensifies

Cash Runway and Pipeline Cuts; The Warning Signs Behind Biopharma Layoffs

As layoffs continue across parts of the biopharma industry in 2026, experts say workforce reductions rarely happen without warning. While many employees focus on cost-cutting measures, industry leaders believe the strongest signals often come from clinical progress, pipeline strategy and
  • News
Cash Runway and Pipeline Cuts; The Warning Signs Behind Biopharma Layoffs

FDA Flags Moderna Flu Vaccine Evidence; Triggering Market and Approval Shock

The U.S. Food and Drug Administration (U.S. Food and Drug Administration) staff have raised concerns about the evidence supporting Moderna’s (Moderna) experimental flu vaccine mFlusiva ahead of a key advisory panel meeting in Washington. Regulators questioned the strength and completeness
  • News
FDA Flags Moderna Flu Vaccine Evidence; Triggering Market and Approval Shock

Neumora MDD Phase III Failure; KOASTAL Trials Collapse Forces Program Shutdown

Neumora Therapeutics has reported three consecutive Phase III failures for its major depressive disorder candidate navacaprant after KOASTAL-2 and KOASTAL-3 failed to meet primary and key secondary endpoints. The company confirmed it will discontinue development of the asset and reduce
  • News
Neumora MDD Phase III Failure; KOASTAL Trials Collapse Forces Program Shutdown

FDA Flags Weight Loss Endpoints as Inadequate; Obesity Trials Under Regulatory Pressure

Regulators and industry stakeholders are reassessing whether body weight alone is a sufficient endpoint for obesity therapies. In a recent Boehringer Ingelheim discussion, Brian Hilberdink highlighted a shift toward metabolic health as a more meaningful indicator of clinical benefit. The
  • News
FDA Flags Weight Loss Endpoints as Inadequate; Obesity Trials Under Regulatory Pressure